257 related articles for article (PubMed ID: 24447434)
1. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R6. PubMed ID: 24447434
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
3. PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
Beelen K; Hoefnagel LD; Opdam M; Wesseling J; Sanders J; Vincent AD; van Diest PJ; Linn SC
Int J Cancer; 2014 Sep; 135(5):1257-63. PubMed ID: 24501006
[TBL] [Abstract][Full Text] [Related]
4. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.
Bostner J; Karlsson E; Pandiyan MJ; Westman H; Skoog L; Fornander T; Nordenskjöld B; Stål O
Breast Cancer Res Treat; 2013 Jan; 137(2):397-406. PubMed ID: 23242584
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
[TBL] [Abstract][Full Text] [Related]
6. CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.
Nguyen Hoang AT; Hoe KL; Lee SJ
PLoS One; 2021; 16(4):e0246264. PubMed ID: 33861751
[TBL] [Abstract][Full Text] [Related]
7. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
8. The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.
Shrivastav A; Bruce M; Jaksic D; Bader T; Seekallu S; Penner C; Nugent Z; Watson P; Murphy L
Breast Cancer Res; 2014 May; 16(3):R49. PubMed ID: 24887419
[TBL] [Abstract][Full Text] [Related]
9. Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
Kruger DT; Beelen KJ; Opdam M; Sanders J; van der Noort V; Boven E; Linn SC
Br J Cancer; 2018 Oct; 119(7):832-839. PubMed ID: 30287915
[TBL] [Abstract][Full Text] [Related]
10. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
Lu PW; Li L; Wang F; Gu YT
J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
[TBL] [Abstract][Full Text] [Related]
14. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
[TBL] [Abstract][Full Text] [Related]
15. Akt kinases in breast cancer and the results of adjuvant therapy.
Stål O; Pérez-Tenorio G; Akerberg L; Olsson B; Nordenskjöld B; Skoog L; Rutqvist LE
Breast Cancer Res; 2003; 5(2):R37-44. PubMed ID: 12631397
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
[TBL] [Abstract][Full Text] [Related]
17. Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes.
Kruger DT; Opdam M; Sanders J; van der Noort V; Boven E; Linn SC
APMIS; 2020 Apr; 128(4):298-307. PubMed ID: 31976581
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
20. AKT activation predicts outcome in breast cancer patients treated with tamoxifen.
Kirkegaard T; Witton CJ; McGlynn LM; Tovey SM; Dunne B; Lyon A; Bartlett JM
J Pathol; 2005 Oct; 207(2):139-46. PubMed ID: 16088978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
